8-K: Allarity Therapeutics Enters Management Services Agreement with Ljungaskog Consulting AB, Replacing Previous Consultancy Deal

Allarity Therapeutics has replaced its existing consultancy agreement with a new Management Services Agreement with Ljungaskog Consulting AB, effective June 1, 2024, outlining the terms of engagement for CEO Thomas H. Jensen.

Summary

• Allarity Therapeutics has entered into a Management Services Agreement (MSA) with Ljungaskog Consulting AB, effective June 1, 2024, replacing a previous consultancy agreement.
• The MSA outlines the terms for Thomas H. Jensen's role as CEO, including a monthly fee of $43,750, paid in two installments.
• A one-time signing bonus of $100,000 is payable within 30 days of the effective date, contingent on Jensen not terminating the agreement within one year or engaging in conduct that would allow the company to terminate for cause.
• Jensen is eligible for a discretionary annual performance bonus, capped at 50% of the total monthly fees paid in a calendar year, based on metrics set by the company.
• The agreement includes provisions for reimbursement of reasonable and necessary expenses, with prior approval required for expenses exceeding $5,000.
• The MSA can be terminated by the company for convenience with 15 days' notice, or by Jensen with 30 days' notice.
• Termination by the company for convenience within 12 months of a change of control results in a 12-month termination fee, otherwise it is 9 months of the monthly fee.
• The company can terminate the agreement immediately for cause, including failure to perform services, material breach, fraud, or other misconduct.
• Jensen can terminate the agreement for good reason, such as a material breach by the company, a reduction in monthly fee, or a change in his CEO title.
• The agreement includes standard clauses for confidentiality, non-solicitation, and indemnification.

Sentiment

Score: 7

Explanation: The document is a standard agreement, with no major positive or negative surprises. The terms are reasonable and expected for a CEO engagement. The sentiment is neutral to slightly positive due to the clarity and structure of the agreement.

Positives

• The new Management Services Agreement provides clarity on the terms of engagement for the CEO.
• The agreement includes a signing bonus of $100,000, indicating a strong commitment from the company to the CEO.
• The potential for a performance bonus provides an incentive for the CEO to achieve company goals.
• The agreement includes a termination payment of 9 months of the monthly fee if terminated for convenience by the company, or 12 months if within 12 months of a change of control, providing some security for the CEO.
• The agreement includes standard clauses for confidentiality, non-solicitation, and indemnification, protecting the company's interests.

Negatives

• The CEO is required to repay the full signing bonus if the agreement is terminated within one year, which could be a risk for the CEO.
• The performance bonus is discretionary and capped at 50% of the monthly fees, which may not be as lucrative as other arrangements.
• The company has the right to terminate the agreement for cause, which could be a risk for the CEO.
• The agreement includes a non-solicitation clause that restricts the CEO's activities for 12 months after termination.

Risks

• The CEO could be terminated for cause if they fail to perform the services, breach the agreement, or engage in misconduct.
• The company has the discretion to adjust the monthly fee based on performance, which could lead to uncertainty for the CEO.
• The performance bonus is discretionary and may not be paid if the company does not deem the performance metrics to be met.
• The CEO is required to repay the signing bonus if the agreement is terminated within one year, which could be a financial risk.

Future Outlook

The agreement is set to continue until terminated as per the provisions of the MSA, subject to any terms agreed by the parties to survive the termination of the MSA. The company will review the monthly fee annually and may adjust it based on performance.

Management Comments

• The Company had announced its intention to amend the Consultancy Agreement to clarify the scope of services to be provided by Mr. Jensen, increase his compensation, and extend the agreements term to December 1, 2024. However, these amendments did not materialize.
• The MSA supersedes and replaces the Consultancy Agreement in its entirety.

Industry Context

This agreement is typical for a publicly traded company engaging a CEO, with standard clauses for compensation, termination, and confidentiality. The agreement is specific to the life sciences industry, as noted in the exclusivity clause.

Comparison to Industry Standards

• The compensation structure, including a base salary, signing bonus, and performance-based bonus, is common for executive roles in publicly traded companies.
• The termination clauses, including termination for convenience and cause, are standard in executive employment agreements.
• The non-solicitation and confidentiality clauses are also typical for agreements of this nature.
• The 9-12 month termination payment is within the range of what is seen in similar agreements, with the 12 month payment triggered by a change of control being a common feature.
• The agreement is similar to those of other small to mid-cap biotech companies, such as those seen at companies like Veru Inc. or Agenus Inc., where the CEO's compensation is a mix of base salary, bonus, and equity.

Stakeholder Impact

• Shareholders will be impacted by the terms of the agreement, as it outlines the compensation and responsibilities of the CEO.
• Employees may be impacted by the CEO's performance and leadership under the new agreement.
• The agreement ensures the continuity of leadership and management for the company.

Next Steps

• The company will pay the signing bonus within 30 days of the effective date.
• The company will determine and approve the performance bonus metrics for each calendar year.
• The company will review the monthly fee annually and may adjust it based on performance.

Key Dates

Keywords

Management Services Agreement, CEO, Thomas H. Jensen, Consulting, Compensation, Termination, Performance Bonus, Allarity Therapeutics, Ljungaskog Consulting AB